April 21 () - AstraZeneca said on Tuesday its rare blood disorder drug Ultomiris has met ‌the main goal of a late-stage trial ...

AstraZeneca (AZN) stock is in focus as tozorakimab marks a new Phase 3 trial win in chronic obstructive pulmonary disease, a ...

AstraZeneca is expanding its prospects in cardiometabolic disease, paying $1.2 billion to begin a partnership on eight programs that include obesity drug candidates with potential advantages over ...

AstraZeneca reported mixed phase 3 data for efzimfotase alfa in hypophosphatasia, with positive results in paediatric patients and a missed primary endpoint in adults. The company plans to move ahead ...

AstraZeneca executives have told Fierce Biotech they still see potential in harnessing the relaxin hormone to treat heart failure despite abandoning work on one of two clinical-stage candidates. As ...